GetReal Institute 2024 Annual Conference: Editor’s highlights evidencebaseonline.com/getreal-instit…

John LaMattina – Drug Price Controls and IP Attacks Get Real omny.fm/shows/vital-he…
John LaMattina PureTech Forbes Duane Schulthess VitalTransformation Better Science Better Health

PODCAST: The Fact Free Attacks on IP
-->bit.ly/4cwv0Ba

Duane Schulthess Bayh-Dole Coalition VitalTransformation Better Science Better Health AAU

Kate Hudson & Joseph P. Allen – The Fact Free Attacks on IP
Bayh-Dole Coalition Kate Hudson I Am Biotech Win Boerckel

omny.fm/shows/vital-he…

The GetReal Institute Annual Conference 2024
A Growing Convergence: RWE for Regulatory & HTA Decision-Making, 14-15 May

What will be discussed and who will participate?
Discover the full programme bit.ly/3TqsBPU

Registration here -> bit.ly/3VnjNNe

PODCAST: NIH money is dwarfed by the funding by industry --> bit.ly/48RPYY9
Duane Schulthess
Bayh-Dole Coalition
I Am Biotech
VitalTransformation
Better Science Better Health

GetReal Conference 14-15 May 2024
A Growing Convergence: RWE for Regulatory and HTA Decision-Making
This year’s event continues the journey to shape the future of RWE in Regulatory and HTA decision-making.
Register now, early bird ends tomorrow!
-> getreal-conference.org

Commentary Boston Business Journal: bit.ly/3Pdpzgk The IRA’s impact on medical innovation by would lead to nearly 230 fewer FDA approvals of new medicines or new uses over 10 years -> the research here by VitalTransformation bit.ly/4a3yzgb The New England Venture Capital Association Ari F. Glantz

The AAM opposes the suggested use of price as a reason to exercise march-in rights, referencing recent research from VitalTransformation bit.ly/49XPiS6 Duane Schulthess -> read their comments here bit.ly/4c6Cv1x

For 15 FDA approved products with patents containing a government interest statement, the total industry contribution was $44.3 billion, while the government contribution was $276 million, 1/160th of the total funding required for their development.

👉 bit.ly/3GnnWYN

NIH’s fair pricing clauses failed when previously tried. They have, “driven industry away from potentially beneficial scientific collaborations . . .without providing an offsetting benefit to the public,” said NIH’s Dr Varmus.

👉 bit.ly/3GnnWYN

Bayh-Dole Coalition
I Am Biotech

Using march-in to control prices will be ineffective – Only 5 of the 361 novel therapies in our cohort include government interest statements covering all mechanism of action and composition of matter patents

Full research 👉 bit.ly/3GnnWYN

Bayh-Dole Coalition I Am Biotech

🗓️MSD Early Bird 👇

Join us on 21 Nov 8.30 am CET for the upcoming Early Bird Debate and engage with two experts as they debate why 1+1 does not equal 3!

us02web.zoom.us/webinar/regist…

MSD Europe #CancerCareDebate VitalTransformation
moderated by Duane Schulthess

PODCAST: bit.ly/3FFmrVl

Bettina Ryll #melanoma #MPNE Duane Schulthess VitalTransformation Better Science Better Health

“IRA Drug Selection Politics Has Investors Fleeing”
PODCAST: bit.ly/48tqtgW

Steven Potts AZBio Duane Schulthess Better Science Better Health VitalTransformation

Amy Millier and the PhRMA Foundation Push the R&D Envelope
PODCAST: bit.ly/48q1ACA

PhRMA Foundation Duane Schulthess @vitaltransform Better Science Better Health

PODCAST: Best-of Vital Health Podcast - looking back on the COVID-19 outbreak
-> bit.ly/3DRKm3i

Duane Schulthess Better Science Better Health Martin Kulldorff Wilfred Reilly

PODCAST: IRA is causing cuts to California biotech R&D

-> bit.ly/44vNI7N

Joe Panetta Biocom California Duane Schulthess Better Science Better Health

PODCAST: Biocom California Grapples with Regulatory Assaults on all Fronts
-> bit.ly/44vNI7N

Duane Schulthess Better Science Better Health Biocom California Joe Panetta

The IRA has Medicare taking the role of a European HTA, this has enormous implications for U.S. Biopharma innovation.
Rhythm I Am Biotech Duane Schulthess Better Science Better Health
omny.fm/shows/vital-he…